Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds - ABC News

Semaglutide is the main ingredient in Wegovy and Ozempic. A recent study found it may help reduce the risk of heart attack and stroke in people without diabetes.
Semaglutide is the main ingredient in medications including Wegovy and Ozempic.
ABC News’ Dr. Jennifer Ashton explains a new study in the New England Journal of Medicine that shows a reduction in heart attacks, strokes and death in overweight or obese participants who took semaglutide.

FDA approves the active ingredient in Mounjaro to help people with obesity lose weight, named Zepbound - Delta Daily News

Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds - ABC News

Wegovy Slashes the Risk of Heart Attack and Stroke in a Landmark Trial

Popular weight loss drug Wegovy also found to lower the risk of heart attacks, strokes - ABC News

Neuralert

Weight-loss drug Wegovy cuts heart attack, stroke risk by 20%, study says

Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit

Remote Health Solutions

Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds - ABC News

Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds - ABC News

What we still don't know about Wegovy's effect on strokes and heart attacks

Remote Health Solutions

Sex Differences in Cardiovascular Consequences of Hypertension, Obesity, and Diabetes: JACC Focus Seminar 4/7

Wegovy study: Semaglutide reduced risks for heart attacks, strokes - UCHealth Today